Skip to content

E34.09

Billable

Other carcinoid syndrome

Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)

Is E34.09 an HCC code?

Yes. E34.09 maps to Metastatic Cancer and Acute Leukemia under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24).

HCC Category Mapping

V28HCC 17Metastatic Cancer and Acute Leukemia
0.368
V24HCC 12Breast, Prostate, and Other Cancers and Tumors
0.150
ESRDHCC 12Breast, Prostate, and Other Cancers and Tumors
0.000
RxHCCHCC 22Cancer, Other Specified Sites
0.000

RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

MEAT Criteria for E34.09

For E34.09 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.

  • MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
  • EEvaluate: test results, medication response, or physical findings reviewed by the provider
  • AAssess: explicit mention in the assessment or plan with acknowledgment of status
  • TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed E34.09 during that encounter — not just copy-forwarded from a problem list.

What This Code Means

E34.09 is the ICD-10-CM diagnosis code for other carcinoid syndrome. Carcinoid syndrome with symptoms other than heart involvement, such as flushing, diarrhea, or bronchospasm caused by hormone-secreting tumors. E34.09 sits in the ICD-10-CM chapter for endocrine, nutritional and metabolic diseases (e00-e89), within the section covering disorders of other endocrine glands (e20-e35).

Under the CMS-HCC V28 risk adjustment model, E34.09 maps to Metastatic Cancer and Acute Leukemia (HCC 17) with a community, non-dual, aged base RAF weight of 0.368. Under the older CMS-HCC V24 model, E34.09 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

Use this code when carcinoid syndrome is documented with manifestations other than cardiac involvement. Because E34.09 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for E34.09 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

  • Use this code when carcinoid syndrome is documented with manifestations other than cardiac involvement
  • Document specific symptoms (flushing, diarrhea, etc.) to support medical necessity and treatment decisions

Clinical Significance

Other carcinoid syndrome captures carcinoid syndrome manifestations that do not involve the heart, such as episodic flushing, secretory diarrhea, bronchospasm, and pellagra-like skin changes. These symptoms result from excessive serotonin and other vasoactive mediators released by neuroendocrine tumors and significantly impact quality of life and nutritional status.

Documentation Requirements

  • Documentation should specify the carcinoid manifestations present (flushing episodes with frequency and triggers, diarrhea with stool frequency, bronchospasm severity, skin changes).
  • Biochemical confirmation through elevated 24-hour urine 5-hydroxyindoleacetic acid or serum chromogranin A should be noted.
  • The underlying neuroendocrine tumor site and treatment status must be documented.
  • An echocardiogram documenting absence of cardiac involvement supports use of this code over E34.01.

Commonly Confused Codes

  • E34.01 (Carcinoid heart syndrome) is used when cardiac valve involvement is present.
  • E34.00 (Carcinoid syndrome, unspecified) is less specific and should be avoided when manifestations are documented.
  • C7A.xxx codes for neuroendocrine tumors should be assigned separately.
  • K58.x (Irritable bowel syndrome) may be confused clinically but has a different etiology.

Code Hierarchy

Open E34.09 in the Interactive Encoder

See full code details, AI coding tips, HCC mappings, and related codes in our interactive encoder. Start your 14-day Pro trial — no credit card required.